BioMed Research International / 2014 / Article / Tab 3

Review Article

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients

Table 3

EMT markers in CTC of breast cancer patients.

AuthorYear MethodEMT markerExpression rate in CTC

Kasimir-Bauer et al. [17]20125021RT-PCRTWIST1, Akt2
PI3K
,
Giordano et al. [18]2012282RT-PCRTWIST1
SNAIL1
ZEB1
TG2
88%*
Barriere et al. [19]2012241RT-PCRTWIST1
Akt2
PI3K
13%
13%
67%
Mego et al. [77]2012212RT-PCRTWIST1
SNAIL1
26%
21%
Armstrong et al. [75]2011162IFCVimentin
N-cadherin
70%
67%
Kallergi et al. [76]2011501,2IFCTWIST1
Vimentin
73%1, 100%2
77%1, 100%2
Mego et al. [74]2011521RT-PCRTWIST1
SNAIL1
SLUG
ZEB1
FoxC2
15,4%*
Raimondi et al. [78]2011921,2RT-PCRVimentin
Fibronectin
28%3, 38%4
18%3, 35%4
Aktas et al. [20]2009392RT-PCRTWIST1
Akt2
PI3K
,

Primary breast cancer, 2metastatic breast cancer, 3CTC positive group, 4CTC negative group; *at least one EMT marker was expressed, PFS: progression free survival.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.